HLB Cell Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.life-liver.co.kr
Study to Evaluate the Safety and Efficacy of HLBLS-200 in Patients Requiring Hemostatic Technique
Not Applicable
Completed
- Conditions
- Hemorrhage
- Interventions
- Device: HLBLS-200
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- HLB Cell Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT03957356
- Locations
- 🇰🇷
Hanyang Univ. Medical Center, Seoul, Korea, Republic of
A Safety and Efficacy Study of Infusions of HepaStem in Urea Cycle Disorders Pediatric Patients
Phase 2
Withdrawn
- Conditions
- Urea Cycle Disorder
- Interventions
- Biological: HepaStem Infusion
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- HLB Cell Co., Ltd.
- Registration Number
- NCT03884959
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Study to Evaluate Safety and Efficacy of LifeLiver in Acute or Acute-on-Chronic Liver Failure Patients
Phase 2
- Conditions
- Acute-On-Chronic Liver FailureAcute Liver Failure
- Interventions
- Combination Product: LifeLiver
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- HLB Cell Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03882346
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath